ADXN

Addex Therapeutics
ADXN

$11.18

1.15%

Market Cap: $12M

About: Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Employees: 23

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

295% more capital invested

Capital invested by funds: $4.99K [Q1] → $19.7K (+$14.7K) [Q2]

100% more funds holding

Funds holding: 1 [Q1] → 2 (+1) [Q2]

0% more ownership

Funds ownership: 0% [Q1] → 0% (+0%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$30

168%

upside

Avg. target

$30

168%

upside

High target

$30

168%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	168%upside $30	Buy Reiterated	28 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	168%upside $30	Buy Upgraded	31 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ADXN published over the past 30 days

Zacks Investment Research

Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel.

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Zacks Investment Research

Addex Stock Soars on Crucial Update From Indivior Research Deal

ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.

Addex Stock Soars on Crucial Update From Indivior Research Deal

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

Why Addex Therapeutics stock skyrocketed 70% on Tuesday

Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.

Why Addex Therapeutics stock skyrocketed 70% on Tuesday

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Addex's Partner Discontinues ADX71149 development in Epilepsy

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.

Addex's Partner Discontinues ADX71149 development in Epilepsy

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM).

Addex Shareholders Approve All Resolutions at Annual General Meeting

See News Rankings